G&S Capital LLC Makes New $2.59 Million Investment in Gilead Sciences, Inc. $GILD

Key Points

• G&S Capital LLC has made a new investment of $2.59 million in Gilead Sciences by acquiring 23,325 shares during the second quarter.
• Analysts have recently increased their price targets for Gilead, with UBS raising it to $112.00 and JPMorgan Chase increasing it to $145.00, reflecting positive market sentiment towards the company.
• Gilead Sciences announced a quarterly dividend of $0.79, representing a 2.8% yield, and has set an EPS guidance of $7.95 to $8.25 for FY 2025.

G&S Capital LLC purchased a new position in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 23,325 shares of the biopharmaceutical company's stock, valued at approximately $2,586,000.

Other large investors have also bought and sold shares of the company. Capital Investment Advisors LLC grew its holdings in shares of Gilead Sciences by 1.5% during the second quarter. Capital Investment Advisors LLC now owns 358,139 shares of the biopharmaceutical company's stock valued at $39,707,000 after buying an additional 5,133 shares during the last quarter. Baron Silver Stevens Financial Advisors LLC grew its holdings in shares of Gilead Sciences by 3.3% during the second quarter. Baron Silver Stevens Financial Advisors LLC now owns 7,077 shares of the biopharmaceutical company's stock valued at $785,000 after buying an additional 228 shares during the last quarter. FARMERS & MERCHANTS TRUST Co OF LONG BEACH purchased a new position in Gilead Sciences during the second quarter worth about $202,000. Moss Adams Wealth Advisors LLC boosted its holdings in Gilead Sciences by 13.5% during the second quarter. Moss Adams Wealth Advisors LLC now owns 4,198 shares of the biopharmaceutical company's stock worth $465,000 after purchasing an additional 498 shares during the last quarter. Finally, GC Wealth Management RIA LLC boosted its holdings in Gilead Sciences by 341.3% during the second quarter. GC Wealth Management RIA LLC now owns 9,480 shares of the biopharmaceutical company's stock worth $1,051,000 after purchasing an additional 7,332 shares during the last quarter. 83.67% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

GILD has been the topic of several analyst reports. UBS Group boosted their price target on shares of Gilead Sciences from $108.00 to $112.00 and gave the stock a "neutral" rating in a report on Friday, August 8th. JPMorgan Chase & Co. boosted their price target on shares of Gilead Sciences from $135.00 to $145.00 and gave the stock an "overweight" rating in a report on Tuesday, September 16th. Dbs Bank raised shares of Gilead Sciences to a "moderate buy" rating in a research report on Friday, September 5th. Needham & Company LLC raised shares of Gilead Sciences from a "hold" rating to a "buy" rating and set a $133.00 price objective on the stock in a research report on Friday, July 25th. Finally, Royal Bank Of Canada lifted their price objective on shares of Gilead Sciences from $96.00 to $98.00 and gave the stock a "sector perform" rating in a research report on Friday, August 8th. Three analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Gilead Sciences presently has an average rating of "Moderate Buy" and an average target price of $117.17.

Insider Transactions at Gilead Sciences

In related news, CFO Andrew D. Dickinson sold 2,500 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares in the company, valued at approximately $18,120,661.35. This trade represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 3,000 shares of Gilead Sciences stock in a transaction dated Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $340,710.00. Following the completion of the transaction, the insider owned 113,193 shares of the company's stock, valued at approximately $12,855,329.01. This represents a 2.58% decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 72,000 shares of company stock valued at $8,285,530. 0.27% of the stock is currently owned by insiders.

Gilead Sciences Stock Up 0.5%

Shares of NASDAQ GILD opened at $112.62 on Tuesday. The company has a current ratio of 1.32, a quick ratio of 1.15 and a debt-to-equity ratio of 1.13. The firm has a fifty day simple moving average of $114.50 and a two-hundred day simple moving average of $109.90. The firm has a market capitalization of $139.74 billion, a PE ratio of 22.43, a price-to-earnings-growth ratio of 0.76 and a beta of 0.36. Gilead Sciences, Inc. has a 12 month low of $82.82 and a 12 month high of $121.83.

Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.96 by $0.05. The business had revenue of $7.08 billion for the quarter, compared to analysts' expectations of $6.95 billion. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The firm's quarterly revenue was up 1.4% on a year-over-year basis. During the same period in the prior year, the firm posted $2.01 EPS. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. Equities analysts expect that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were issued a $0.79 dividend. This represents a $3.16 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Monday, September 15th. Gilead Sciences's payout ratio is 62.95%.

Gilead Sciences Company Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.